In nonresponders with chronic hepatitis C, a preliminary blinded safety analysis suggested that both regimens (with and without Talpha1 added to peg-IFN-alpha2a and ribavirin) were well tolerated.
In plain wordsIn people with hepatitis C who had not responded to earlier treatment, a first blinded safety check suggested both treatment regimens were well tolerated.
- Peptide
- Thymosin alpha-1
- Outcome
- No significant changeTolerability in preliminary blinded safety analysis
- Study
n: not reported in source
- Outcome group
- Adverse events · Infection
Source sentences
Preliminary blinded safety analysis suggests that both regimens are well tolerated.
2 context sentences(design, population, supporting numbers)
We designed a phase 3, randomized, double-blind, multicenter, prospective, placebo controlled study.
Patients meeting selection criteria were randomized centrally (through IVR system) to receive either peg-IFN-alpha2a 180 mcg s.c. once weekly + Ribavirin 1000-1200 mg p.o. daily + Talpha1 1.6 mg s.c. twice weekly for 24 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.